New approaches to treating Alzheimer's disease

Perspectives in Medicinal Chemistry
H ZhengMoussa B H Youdim

Abstract

To date, no truly efficacious drugs for Alzheimer's disease (AD) have been developed; moreover, all new anti-AD drugs developed since 2003 have failed. To succeed where previous ones have failed in drug development, new approaches for AD therapy are needed. Here we discuss the potential application of network medicine as a new approach to AD treatment. Unlike traditional approaches focused on a single target/pathway, network medicine targets and restores disease-disrupted networks through simultaneous modulation of numerous proteins (targets)/pathways involved in AD pathogenesis. We consider several drug candidates under development for AD therapy, including Keap1-Nrf2 regulators, endogenous neurogenic agents, and hypoxia-inducible factor 1 (HIF-1) activators. These drug candidates are multi-target ligands with the potential to further develop as network medicines, since they act as master regulators to initiate a broad range of cellular defense mechanisms/cytoprotective genes that exert their efficacy in a holistic way. We also explore their diverse mechanisms of action and potential disease-modifying effects, which may have profound implications for drug discovery.

References

Jun 1, 1991·Lancet·D R Crapper McLachlanD F Andrews
Oct 1, 1985·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J A WalkerR P Eisinger
May 13, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jun Ming WangRoberta Diaz Brinton
Dec 13, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Xi-Lin ChenCharles Kunsch
Feb 24, 2007·Nature Reviews. Drug Discovery·Hiroaki Kitano
Jun 10, 2008·CNS & Neurological Disorders Drug Targets·Andrea AbdipranotoBryce Vissel
Jun 14, 2008·Psychopharmacology·Kristiina KaskInger Sundström-Poromaa
Oct 22, 2008·Nature Chemical Biology·Andrew L Hopkins
Nov 11, 2008·Recent Patents on CNS Drug Discovery·Gilbert M Rishton
Jun 13, 2009·The European Journal of Neuroscience·David SchubertBarbara Blouw
Jul 30, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Lana KupershmidtMoussa B H Youdim
Sep 19, 2009·Cellular and Molecular Life Sciences : CMLS·O O Ogunshola, X Antoniou
Sep 25, 2009·The New England Journal of Medicine·C Warren OlanowUNKNOWN ADAGIO Study Investigators
Oct 23, 2009·Journal of Neurochemistry·Sónia C Correia, Paula I Moreira
Jan 26, 2010·Antioxidants & Redox Signaling·Orly WeinrebMoussa B H Youdim
Mar 17, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jun Ming WangRoberta Diaz Brinton
Jul 6, 2010·Progress in Neurobiology·Orly WeinrebMoussa B H Youdim
Jul 27, 2010·Radiology·Hong-Ying ZhangGao-Jun Teng
Aug 24, 2010·The European Journal of Neuroscience·Laura K HamiltonKarl J L Fernandes
Dec 18, 2010·Nature Reviews. Genetics·Albert-László BarabásiJoseph Loscalzo
Jan 8, 2011·Journal of the American Chemical Society·Karen S MacMillanJoseph M Ready
Jan 22, 2011·Central Nervous System Agents in Medicinal Chemistry·Philippe Taupin
Jun 10, 2011·Brain : a Journal of Neurology·Lukas HaiderHans Lassmann
Aug 25, 2011·Current Medicinal Chemistry·Z ZhangH Shi
Oct 12, 2011·The Journal of Experimental Medicine·Kamran GhoreschiMartin Röcken
Oct 25, 2011·Biochimica Et Biophysica Acta·Patrizia Mecocci, Maria Cristina Polidori
Dec 24, 2011·Molecular Neurodegeneration·Yangling Mu, Fred H Gage
Mar 13, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Mar 20, 2012·Mechanisms of Ageing and Development·Lana KupershmidtOrly Weinreb
Apr 13, 2012·Journal of Alzheimer's Disease : JAD·Sara K BengtssonMingde Wang

❮ Previous
Next ❯

Citations

Oct 17, 2015·Journal of Natural Products·Jing XuYuanqiang Guo
Apr 14, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Federica PratiMaria Laura Bolognesi
Aug 24, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mar Cuadrado-TejedorAna Garcia-Osta
May 8, 2020·Biological & Pharmaceutical Bulletin·Min YangFu-Sheng Wang
Oct 11, 2017·Journal of Cellular and Molecular Medicine·Michela CampoloEmanuela Esposito
Aug 30, 2020·Neural Regeneration Research·Halimatu Hassan, Ruoli Chen
Jan 2, 2016·Pharmacological Reports : PR·Justyna GodyńBarbara Malawska
Jul 3, 2021·Metabolic Brain Disease·Xiaorong ZhaoBo Niu

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
transgenic

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

EMBO Molecular Medicine
Dale E Bredesen, Varghese John
Beginnings : the Official Newsletter of the American Holistic Nurses' Association
R S Ivker
Current Medicinal Chemistry
N A Warfel, W S El-Deiry
© 2022 Meta ULC. All rights reserved